Diosmin + Hesperidin (Daflon ®1000).
The #1 doctor recommended
non-prescription brand for
Chronic Venous Insufficiency and Hemorrhoids. 1
ALSO AVAILABLE IN ALL LEADING DRUGSTORES NATIONWIDE
Daflon 1000, 30 tablets: for Hemorrhoidal Disease.
3 tablets a day for the first 4 days. 2 tablets a day for the next 3 days. Then 1 tablet a day for 2 months for continuous protection.
Daflon 1000mg, 30 tablets : for Chronic Venous Insufficiency.
1 tablet a day. For use beyond 2 months consult your doctor
Safety Information:
Diosmin + Hesperidin (Daflon®) 1000mg Safety Information
COMPOSITION: Micronized, purified flavonoid fraction 1000 mg: 900 mg diosmin; 100 mg flavonoids expressed as hesperidin.
INDICATIONS: Treatment of organic and idiopathic chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs; pain; nocturnal cramps. Treatment of hemorrhoids and acute hemorrhoidal attacks.
DOSAGE AND ADMINISTRATION: In venous disease: 1000 mg daily. In acute hemorrhoidal attacks: 3000 mg per day for the first 4 days, then 2000 mg per day for 3 days. Method of administration: Oral route.
CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients.
WARNINGS: The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions. The treatment must be short-term. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed. Excipients: sodium-free.
INTERACTION: None.
PREGNANCY/LACTATION: Treatment should be avoided.
UNDESIRABLE EFFECTS: Common: diarrhea, dyspepsia, nausea, vomiting. Uncommon: colitis. Rare: dizziness, headache, malaise, rash, pruritus, urticaria. Frequency not known: abdominal pain, isolated face, lip, eyelid edema. Exceptionally, Quincke’s edema. PROPERTIES: Vascular protector and venotonic. Daflon acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance. PRESENTATION: Pack of 30 film-coated tablets. STORAGE: Store at temperatures not exceeding 30°C.
For suspected adverse drug reaction, report to the FDA at www.fda.gov.ph. SERVIER PHILIPPINES, INC. Unit AD, 11th Floor, 8 Rockwell, Hidalgo Drive, Rockwell Center, Makati City, 1210.
Further information available upon request.
Diosmin + Hesperidin (Daflon®) 500mg Safety Information
COMPOSITION: Micronized, purified flavonoid fraction 500 mg: 450 mg diosmin; 50 mg flavonoids expressed as hesperidin. INDICATIONS: Treatment of organic and idiopathic chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs; pain; nocturnal cramps. Treatment of hemorrhoids and acute hemorrhoidal attacks. DOSAGE AND ADMINISTRATION: In venous disease: 1000 mg daily. In acute hemorrhoidal attacks: 3000 mg per day for the first 4 days, then 2000 mg per day for 3 days. Method of administration: Oral route. CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients. WARNINGS: The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions. The treatment must be short-term. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed. Excipients: sodium-free. INTERACTION: None. PREGNANCY/LACTATION: Treatment should be avoided. UNDESIRABLE EFFECTS: Common: diarrhea, dyspepsia, nausea, vomiting. Uncommon: colitis. Rare: dizziness, headache, malaise, rash, pruritus, urticaria. Frequency not known: abdominal pain, isolated face, lip, eyelid edema. Exceptionally, Quincke’s edema. PROPERTIES: Vascular protector and venotonic. Daflon acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance. PRESENTATION: Pack of 30 film-coated tablets. STORAGE: Store at temperatures not exceeding 30°C.
For suspected adverse drug reaction, report to the FDA at www.fda.gov.ph. SERVIER PHILIPPINES, INC. Unit AD, 11th Floor, 8 Rockwell, Hidalgo Drive, Rockwell Center, Makati City, 1210.
Further information available upon request.
References:
1. IQVIA Daflon sales data MAT Q2 2021.
2024